LT2954892T - Solidinės kompozicijos - Google Patents

Solidinės kompozicijos

Info

Publication number
LT2954892T
LT2954892T LTEP15176068.3T LT15176068T LT2954892T LT 2954892 T LT2954892 T LT 2954892T LT 15176068 T LT15176068 T LT 15176068T LT 2954892 T LT2954892 T LT 2954892T
Authority
LT
Lithuania
Prior art keywords
solid compositions
compositions
solid
Prior art date
Application number
LTEP15176068.3T
Other languages
English (en)
Inventor
Bernd Liepold
Tina Jung
Peter Holig
Rudolf Schroeder
Nancy E. Sever
Justin Lafountaine
Brent D. Sinclair
Yi Gao
Jianwei Wu
Bryan K. Erickson
Simon Kullmann
Ulrich Westedt
Mirko Pauli
Tanja Heitermann
Renato Koenig
Madlen Thiel
Gerd Woehrle
Original Assignee
Abbvie Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44317041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2954892(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/813,301 external-priority patent/US8691938B2/en
Application filed by Abbvie Ireland Unlimited Company filed Critical Abbvie Ireland Unlimited Company
Publication of LT2954892T publication Critical patent/LT2954892T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LTEP15176068.3T 2010-06-10 2011-06-09 Solidinės kompozicijos LT2954892T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35355310P 2010-06-10 2010-06-10
US12/813,301 US8691938B2 (en) 2009-06-11 2010-06-10 Anti-viral compounds

Publications (1)

Publication Number Publication Date
LT2954892T true LT2954892T (lt) 2018-12-10

Family

ID=44317041

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15176068.3T LT2954892T (lt) 2010-06-10 2011-06-09 Solidinės kompozicijos

Country Status (41)

Country Link
US (2) US8686026B2 (lt)
EP (3) EP2579854B2 (lt)
JP (1) JP5814356B2 (lt)
KR (3) KR20180023014A (lt)
CN (1) CN103209686B (lt)
AR (1) AR083240A1 (lt)
AU (1) AU2011264823B2 (lt)
BR (2) BR212012031500U2 (lt)
CA (1) CA2802180C (lt)
CL (1) CL2012003470A1 (lt)
CO (1) CO6660490A2 (lt)
CR (1) CR20120650A (lt)
CY (2) CY1116748T1 (lt)
DK (2) DK2954892T3 (lt)
DO (1) DOP2012000307A (lt)
EA (1) EA024538B1 (lt)
EC (1) ECSP13012382A (lt)
ES (2) ES2546767T5 (lt)
GT (1) GT201200332A (lt)
HR (2) HRP20150926T4 (lt)
HU (2) HUE039719T2 (lt)
IL (1) IL223535A (lt)
LT (1) LT2954892T (lt)
ME (1) ME02201B (lt)
MX (1) MX2012014384A (lt)
MY (1) MY164607A (lt)
NZ (1) NZ605440A (lt)
PE (1) PE20131036A1 (lt)
PH (1) PH12012502442A1 (lt)
PL (2) PL2954892T3 (lt)
PT (2) PT2579854E (lt)
RS (2) RS54282B2 (lt)
SG (1) SG186251A1 (lt)
SI (2) SI2579854T2 (lt)
SM (2) SMT201800532T1 (lt)
TR (1) TR201815161T4 (lt)
TW (1) TWI487700B (lt)
UA (1) UA105434C2 (lt)
UY (1) UY33446A (lt)
WO (1) WO2011156578A1 (lt)
ZA (1) ZA201300112B (lt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI402070B (zh) 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2730572B1 (en) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
AU2012293619B2 (en) 2011-08-10 2017-05-04 Janssen Sciences Ireland Uc Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015100275B4 (en) * 2011-10-21 2015-06-11 Abbvie Ireland Unlimited Company Methods for treating HCV
WO2013101552A1 (en) * 2011-12-28 2013-07-04 Abbvie Inc. Methods for treating hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2857339C (en) * 2011-12-29 2015-11-17 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104363898A (zh) * 2012-05-07 2015-02-18 百时美施贵宝爱尔兰控股公司 [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
EP2950786B1 (en) * 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
UA116237C2 (uk) * 2013-03-15 2018-02-26 Бьорінгер Інгельхайм Інтернаціональ Гмбх Тверда пероральна дозована композиція інгібітору нсv в аморфному стані
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20160296463A1 (en) * 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
JP6232262B2 (ja) * 2013-11-13 2017-11-15 アクアス株式会社 徐放性を有する固形水処理剤、およびその製造方法
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US10117836B2 (en) * 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
WO2015171162A1 (en) * 2014-05-09 2015-11-12 Abbvie Inc. Anti-viral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
EP3313378A1 (en) * 2015-06-26 2018-05-02 AbbVie Inc. Solid pharmaceutical compositions for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN107735080B (zh) * 2015-07-03 2020-10-23 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
SG10202002900YA (en) * 2015-07-17 2020-05-28 Abbvie Inc Solid pharmaceutical compositions for treating hcv
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017088730A1 (zh) * 2015-11-23 2017-06-01 正大天晴药业集团股份有限公司 用于抗丙型肝炎病毒感染的含硅化合物
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3070563A1 (en) * 2017-07-20 2019-01-24 Amri Ssci, Llc Amorphous dispersions of epigallocatechin gallate
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
KR102286706B1 (ko) 2020-09-29 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조방법
KR102286707B1 (ko) 2020-10-30 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조방법 및 제조장치
KR102286709B1 (ko) 2020-11-03 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조장치
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
US353553A (en) 1886-11-30 Du bois f
US813301A (en) 1903-09-09 1906-02-20 Frank S Hyde Steam-engine.
US5830867A (en) 1993-05-24 1998-11-03 Smithkline Beecham Corporation Hemoregulatory peptides for stimulating the myelopoietic system
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
BR9910640A (pt) 1998-05-22 2001-10-30 Avanir Pharmaceuticals Compostos possuindo propriedades que afetam aige
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ES2245955T3 (es) 1999-12-21 2006-02-01 Sugen, Inc. 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
AU2001253124A1 (en) 2000-04-05 2001-10-23 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
US7309703B2 (en) 2000-08-14 2007-12-18 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6388093B1 (en) 2001-01-05 2002-05-14 Sun Chemical Corporation Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles
CZ20033368A3 (en) 2001-06-11 2004-04-14 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
WO2003105855A1 (en) 2002-01-11 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP3925265B2 (ja) 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ES2319775T3 (es) 2003-10-27 2009-05-12 Vertex Pharmaceuticals Incorporated Combinaciones para el tratamiento del vhc.
BRPI0401908A (pt) 2004-06-04 2006-01-17 Univ Rio De Janeiro Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005287407B2 (en) 2004-07-27 2011-11-17 Gilead Sciences, Inc. Imidazo(4,5-d)pyrimidines, their uses and methods of preparation
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
CN101111489A (zh) 2005-02-01 2008-01-23 惠氏公司 作为β-分泌酶的抑制剂的氨基-吡啶
KR20070102751A (ko) 2005-02-14 2007-10-19 와이어쓰 β-세크레타제 억제제로서의 아졸릴아실구아니딘
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
US7629340B2 (en) 2005-12-12 2009-12-08 Smithkline Beecham Corporation N-(6-membered aromatic ring)-amido anti-viral compounds
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
BRPI0712680A2 (pt) 2006-06-08 2012-11-20 Lilly Co Eli antagonistas de receptor de mch
WO2007144174A1 (en) 2006-06-16 2007-12-21 Syngenta Participations Ag Ethenyl carboxamide derivatives useful as microbiocides
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090004140A1 (en) 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
MX2010001400A (es) 2007-08-03 2010-04-22 Schering Corp Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MX2010008699A (es) 2008-02-12 2010-08-30 Bristol Myers Squibb Co Derivados heterociclicos como inhibidores de virus de la hepatitis c.
DK2242752T3 (da) 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103585127A (zh) 2008-02-28 2014-02-19 Abbvie公司 片剂和其制备方法
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
AU2009261919A1 (en) 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
DK2310095T3 (da) 2008-07-22 2012-12-10 Merck Sharp & Dohme Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
US20120009141A1 (en) 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010059858A1 (en) 2008-11-19 2010-05-27 Duke University Manassantin compounds and methods of making and using same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065681A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EA024853B1 (ru) 2008-12-03 2016-10-31 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
HRP20160476T1 (hr) 2009-03-27 2016-06-03 Merck Sharp & Dohme Corp. Inhibitori replikacije virusa hepatitisa c
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
CN102388046A (zh) 2009-04-08 2012-03-21 巴斯夫欧洲公司 吡咯并吡咯衍生物、其制备及作为半导体的用途
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
MX2011011136A (es) 2009-04-24 2011-11-18 Tibotec Pharm Ltd Eteres diarilicos.
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
SI3309157T1 (sl) 2009-05-13 2020-02-28 Gilead Pharmasset Llc Protivirusne spojine
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
TWI402070B (zh) * 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
EP2473503B1 (en) 2009-09-03 2014-07-23 Janssen R&D Ireland Bis-benzimidazole derivatives
JP5795316B2 (ja) 2009-09-04 2015-10-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド 化合物
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
TWI429645B (en) 2009-12-04 2014-03-11 Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
CN104341401B (zh) 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CN102883718A (zh) 2009-12-24 2013-01-16 顶点制药公司 用于治疗或预防黄病毒感染的类似物
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
CA2787309A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (zh) 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2800530A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
TW201201801A (en) 2010-06-09 2012-01-16 Presidio Pharmaceuticals Inc Inhibitors of HCV NS5A protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
JP5619289B2 (ja) 2010-09-24 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP2621501A4 (en) 2010-09-29 2014-04-09 Merck Sharp & Dohme POLYCYCLIC HETEROCYCLUS DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
BR112013007696A2 (pt) 2010-09-29 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, usos do referido composto e da referida composição
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
CA2814534A1 (en) 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
TWI548629B (zh) 2010-11-17 2016-09-11 吉李德製藥公司 抗病毒化合物
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
KR20150008151A (ko) 2015-01-21
PT2579854E (pt) 2015-10-16
PL2579854T3 (pl) 2015-12-31
DK2579854T4 (en) 2018-10-22
KR20180023014A (ko) 2018-03-06
RS54282B1 (sr) 2016-02-29
BR112012031500A2 (lt) 2015-11-17
MY164607A (en) 2018-01-30
ECSP13012382A (es) 2013-03-28
PE20131036A1 (es) 2013-10-20
HRP20150926T4 (hr) 2018-11-30
JP5814356B2 (ja) 2015-11-17
NZ605440A (en) 2014-05-30
HUE039719T2 (hu) 2019-01-28
CL2012003470A1 (es) 2013-02-15
EP2579854B2 (en) 2018-07-04
PH12012502442A1 (en) 2022-03-21
ES2691625T3 (es) 2018-11-28
SI2579854T2 (sl) 2018-10-30
SG186251A1 (en) 2013-01-30
EA201291394A1 (ru) 2013-05-30
PT2954892T (pt) 2018-11-09
ME02201B (me) 2016-02-20
EP2579854B1 (en) 2015-07-15
DOP2012000307A (es) 2013-01-31
KR101481395B1 (ko) 2015-01-13
TWI487700B (zh) 2015-06-11
CN103209686A (zh) 2013-07-17
ES2546767T5 (es) 2018-07-27
EP2954892A1 (en) 2015-12-16
CY1116748T1 (el) 2017-03-15
DK2954892T3 (en) 2018-10-29
AU2011264823B2 (en) 2014-03-13
SMT201800532T1 (it) 2018-11-09
BR112012031500A8 (pt) 2022-11-01
ZA201300112B (en) 2013-09-25
CO6660490A2 (es) 2013-04-30
PL2579854T5 (pl) 2018-12-31
UY33446A (es) 2012-01-31
CY1122267T1 (el) 2020-07-31
US20140171481A1 (en) 2014-06-19
TR201815161T4 (tr) 2018-11-21
RS57982B1 (sr) 2019-01-31
DK2579854T3 (en) 2015-10-19
EP3456318A1 (en) 2019-03-20
UA105434C2 (uk) 2014-05-12
GT201200332A (es) 2014-11-06
CN103209686B (zh) 2015-06-17
HUE025758T2 (en) 2016-04-28
EP2579854A1 (en) 2013-04-17
CA2802180C (en) 2018-12-18
ES2546767T3 (es) 2015-09-28
AR083240A1 (es) 2013-02-13
TW201204713A (en) 2012-02-01
SI2579854T1 (sl) 2015-09-30
HK1184068A1 (zh) 2014-01-17
KR20130053440A (ko) 2013-05-23
US8686026B2 (en) 2014-04-01
CA2802180A1 (en) 2011-12-15
US20120258909A1 (en) 2012-10-11
MX2012014384A (es) 2013-05-01
WO2011156578A1 (en) 2011-12-15
HRP20181658T1 (hr) 2019-01-11
KR102059386B1 (ko) 2019-12-26
BR212012031500U2 (pt) 2015-11-17
PL2954892T3 (pl) 2019-02-28
JP2013528225A (ja) 2013-07-08
EA024538B1 (ru) 2016-09-30
HRP20150926T1 (xx) 2015-10-09
SMT201500263B (it) 2016-01-08
SI2954892T1 (sl) 2019-01-31
IL223535A (en) 2017-02-28
RS54282B2 (sr) 2018-08-31
AU2011264823A1 (en) 2013-01-24
EP2954892B1 (en) 2018-07-18
CR20120650A (es) 2013-05-16

Similar Documents

Publication Publication Date Title
HRP20181658T1 (hr) Kruti pripravci
ZA201207093B (en) Solid compositions
HRP20171343T1 (hr) Mješavine
GB201009549D0 (en) Compositions
GB201002983D0 (en) Nutritinal composition
GB201019297D0 (en) Improved compositions
GB201009546D0 (en) Compositions
PL2579859T3 (pl) Kompozycja stała zawierająca iwabradynę
GB201010954D0 (en) Compositions
EP2625231A4 (en) INK PRESERVATIVE COMPOSITIONS
GB201002861D0 (en) Compositions
GB201016970D0 (en) Composition
IL225952A0 (en) preparations@rokkhot
GB201014591D0 (en) Compositions
GB201007790D0 (en) Compositions
GB201004717D0 (en) Composition
GB201019606D0 (en) Compositions
GB201008043D0 (en) Compositions
GB201006175D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
GB201012588D0 (en) Compositions
GB201008369D0 (en) Compositions
GB201012508D0 (en) Compositions
GB201005378D0 (en) Composition